Bicuspid aortic valve disease is the most prevalent congenital heart disease, and a challenging aspect of BAV management is the wide variability of phenotypic expressions. This range highlights the importance of a consistent, comprehensive, and straightforward approach for describing this variability. Dr. Michelena will review the new international consensus statement on BAV nomenclature.
For the young BAV patient, new advancements in aortic valve repair are providing significant benefits of improved durability and freedom from lifelong anticoagulation therapy. However, the heterogeneity of BAV presentation similar presents challenges for repair. Dr. Marc Gerdisch and Dr. Joshua Baker review advances in valve repair for the many forms of BAV and AR presentation.